E-Mail
TAMPA, Fla. Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn t work for every patient. Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients have a better CAR T response than others and what can be done to improve the treatment s effectiveness. In a new study published in
AML Genomic Landscape Plays Key Role in Treatment pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
the recent brought together three expert leaders in their field:
moderator Vinay Prasad, MD, is joined by Aaron Goodman, MD, and Al-Ola Abdallah, MD, for a virtual roundtable discussion on the new and potentially practice-changing data from the meeting.
In episode one, the physicians debated the follow-up analysis of a trial that questioned the necessity of early versus delayed ASCT, in light of newer therapies we have today.
In episode two, Dr. Prasad asked if selinexor, recently approved with support from the phase III BOSTON study, a good drug for the treatment of adults with multiple myeloma who have received at least one prior therapy?
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results
January 29, 2021 GMT
Eli Lilly and Company logo. (PRNewsfoto/Eli Lilly and Company)
INDIANAPOLIS, Jan. 29, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2020. $ in millions, except
31%
Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP), include all revenue and expenses recognized during the periods, and reflect Elanco Animal Health (Elanco) as discontinued operations during the first quarter of 2019. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release, and ass
Federal committee recommends more research, care for patients with sickle cell Sickle cell patients may experience frequent infections, fatigue, pain, eye problems and a higher risk of stroke. (Source: Cronkite News) By Harry Croton | January 28, 2021 at 7:58 AM MST - Updated January 29 at 1:28 PM
PHOENIX â Health care experts are calling on federal and state agencies to take action to provide better care for the estimated 100,000 Americans who suffer from sickle cell disease.
Sickle cell is the most common inherited blood disorder in the U.S. and disproportionately affects African Americans, occurring in 1 out of every 365 births of Black children, according to the U.S. Centers for Disease Control and Prevention. Sickle cell patients may experience frequent infections, fatigue, pain, eye problems and a higher risk of stroke.